![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Eli Lilly’s COVID-19 Antibody Cocktail Receives EMA Review
Eli Lilly’s COVID-19 Antibody Cocktail Receives EMA Review
![Eli Lilly logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Eli-Lilly-logo.gif?t=1616695830&width=430)
February 9, 2021
The European Medicines Agency (EMA) is reviewing Eli Lilly’s antibody cocktail as a potential treatment for COVID-19 patients who don’t require supplemental oxygen and are at high risk of progressing to severe disease.
Preliminary study data on Lilly’s bamlanivimab/etesevimab cocktail showed the combination treatment reduced viral load as well as COVID-19-associated medical visits and hospitalizations and the EMA’s human medicines committee is considering a recommendation for conditional marketing authorization.
Results from a phase 3 study showed the antibody cocktail reduced the risk of COVID-19 hospitalization or death by 70 percent.
Upcoming Events
-
21Oct